Assessing the Feasibility of a Pharmacist-Integrated Collaborative Care Model for Opioid Use Disorder: A Nonrandomized Clinical Trial

By
Felicity Homsted
David A. Fiellin
Udi E. Ghitza
Vernon T. Gardner
Bethany McLeman
Paul J. Joudrey
Gerald Cochran
Sarah K. Moore
Lisa Saldana
Edward Chongsi
Kimberly Kramer
Ashley Vena
Rebecca A. Ottesen
Jacklyn Harris
Jesse S. Boggis
Deepika Rao
Owen Murray
Scott Gerlach
Phoebe Gauthier
Katie P. Osterhage
Laura-Mae Baldwin
Lisa A. Marsch
October 14, 2026

Journal Of General Internal Medicine

Objective:

To assess the feasibility and acceptability of implementing pharmacist-integrated medication treatment for opioid use disorder (PrIMO) in varied primary care settings, and to examine preliminary implementation outcomes.

Approach:

Design and setting: A nonrandomized, unassigned, unblinded mixed-methods longitudinal feasibility and implementation trial conducted at four primary care sites in the Northeast, Midwest, Northwest, and Southwest US from August 2022 to July 2024.
Intervention: PrIMO integrated pharmacists into interdisciplinary OUD care teams. Its six core components were collaborative communication, weekly clinical huddles, provider and patient education, comorbidity screening, and education for local partners.
Assessment: The primary feasibility measure was the Stages of Implementation Completion instrument, tailored to 61 milestones. Launch of services was the binary feasibility indicator. Staff and patient surveys assessed acceptability and other implementation outcomes.

Key Findings:

The supplied article context describes the study design, intervention, and planned outcome measures but does not report trial results.

Interpretation:

The study was designed to evaluate whether PrIMO could be implemented across diverse primary care settings; the provided context does not establish its results.